Literature DB >> 30302193

Development of shellfish allergy after exposure to dual immune checkpoint blockade.

Zachary J Brown1, Bernd Heinrich1, Tim F Greten1.   

Abstract

Hepatocellular carcinoma (HCC) is a major health problem worldwide with limited systemic therapies available. Immunotherapy is a fast-moving field that is quickly evolving as a treatment for HCC with three recent clinical trials published treating HCC with immune checkpoint inhibitors with promising results. Checkpoint inhibition may lead to a unique adverse event profile with the potential to cause immune-related adverse events by unbalancing the immune system. Here, we report a case of a 61-year-old male with advanced HCC who developed a shellfish allergy after completing three cycles of combination of tremelimumab and durvalumab therapy.

Entities:  

Keywords:  allergy; checkpoint inhibitors; durvalumab; hepatocellular carcinoma; immunotherapy; tremelimumab

Year:  2018        PMID： 30302193      PMCID： PMC6168040          DOI： 10.2217/hep-2017-0021

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


  16 in total

Review 1.  A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.

Authors:  T W Chen; A R Razak; P L Bedard; L L Siu; A R Hansen
Journal:  Ann Oncol       Date:  2015-04-17       Impact factor: 32.976

2.  Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration.

Authors:  A A Zukiwski; C L David; J Coan; S Wallace; J U Gutterman; G M Mavligit
Journal:  Cancer       Date:  1990-04-01       Impact factor: 6.860

Review 3.  IL-2: the first effective immunotherapy for human cancer.

Authors:  Steven A Rosenberg
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

4.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

Review 5.  Shellfish allergy.

Authors:  A L Lopata; R E O'Hehir; S B Lehrer
Journal:  Clin Exp Allergy       Date:  2010-04-19       Impact factor: 5.018

6.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

7.  Delayed reactions to contrast media after interleukin-2 immunotherapy.

Authors:  P L Choyke; D L Miller; M T Lotze; J M Whiteis; B Ebbitt; S A Rosenberg
Journal:  Radiology       Date:  1992-04       Impact factor: 11.105

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

Review 9.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Authors:  J M Michot; C Bigenwald; S Champiat; M Collins; F Carbonnel; S Postel-Vinay; A Berdelou; A Varga; R Bahleda; A Hollebecque; C Massard; A Fuerea; V Ribrag; A Gazzah; J P Armand; N Amellal; E Angevin; N Noel; C Boutros; C Mateus; C Robert; J C Soria; A Marabelle; O Lambotte
Journal:  Eur J Cancer       Date:  2016-01-05       Impact factor: 9.162

Review 10.  Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers.

Authors:  Benjamin L Maughan; Erin Bailey; David M Gill; Neeraj Agarwal
Journal:  Front Oncol       Date:  2017-04-03       Impact factor: 6.244
View more
  1 in total

1.  The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.

Authors:  Ioannis A Ziogas; Alexandros P Evangeliou; Lipika Goyal; Georgios Tsoulfas; Dimitrios Giannis; Muhammad H Hayat; Konstantinos S Mylonas; Samer Tohme; David A Geller; Nahel Elias
Journal:  Oncologist       Date:  2021-01-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.